FDA Approves Tecentriq Immunotherapy for Specific Type of Advanced Lung Cancer. The U.S. Food and Drug Administration (FDA) approved Genentechâ€™s Tecentriq (atezolizumab) as a treatment for people with metastatic non-small cell lung cancer (NSCLC).